Latest Articles
GLP-1–Progestin and Endometrial Cancer Risk - Conexiant
GLP-1–Progestin and Endometrial Cancer Risk Conexiant
Published: March 2, 2026, 5:01 p.m.
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... - Medical Dialogues
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... Medical Dialogues
Published: Feb. 17, 2026, 3:15 p.m.
Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk - geneonline.com
Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk geneonline.com
Published: Feb. 16, 2026, 6:10 a.m.
Study Finds GLP-1 Agonists Combined with Progestin Reduce Endometrial Cancer Risk by 66% - geneonline.com
Study Finds GLP-1 Agonists Combined with Progestin Reduce Endometrial Cancer Risk by 66% geneonline.com
Published: Feb. 16, 2026, 5:37 a.m.
GLP-1s Plus Progestins Tied to Lower Endometrial Cancer Risk - Medscape
GLP-1s Plus Progestins Tied to Lower Endometrial Cancer Risk Medscape
Published: Feb. 11, 2026, 8:49 a.m.
GLP-1 Receptor Agonists Combined with Progestins and Their Impact on - Bioengineer.org
GLP-1 Receptor Agonists Combined with Progestins and Their Impact on Bioengineer.org
Published: Feb. 10, 2026, 6:37 p.m.
GLP-1 Receptor Agonists Combined with Progestins and Their Impact on - BIOENGINEER.ORG
GLP-1 Receptor Agonists Combined with Progestins and Their Impact on BIOENGINEER.ORG
Published: Feb. 10, 2026, 6:37 p.m.
KU Cancer Center Evaluating Progestin Use to Treat Endometrial Cancer | Newswise - Newswise
KU Cancer Center Evaluating Progestin Use to Treat Endometrial Cancer | Newswise Newswise
Published: Sept. 26, 2025, 1:45 p.m.
KU Cancer Center evaluating progestin use to treat endometrial cancer - University of Kansas Medical Center
KU Cancer Center evaluating progestin use to treat endometrial cancer University of Kansas Medical Center
Published: Sept. 25, 2025, 8:16 p.m.
FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation - Nature
FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation Nature
Published: Sept. 13, 2025, 5:58 a.m.
Link copied to clipboard!